South Street Advisors’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$18.7M Buy
238,689
+5,749
+2% +$392K 2.43% 20
2026
Q1
$15.1M Buy
232,940
+1,182
+0.5% +$83.3K 2.18% 20
2025
Q4
$15.6M Sell
231,758
-16,094
-6% -$1.08M 2.19% 21
2025
Q3
$18.2M Buy
247,852
+6,584
+3% +$437K 2.38% 20
2025
Q2
$12.6M Sell
241,268
-2,342
-1% -$133K 1.86% 23
2025
Q1
$15.5M Buy
243,610
+13,845
+6% +$804K 2.54% 18
2024
Q4
$11M Buy
229,765
+58,350
+34% +$2.99M 1.68% 28
2024
Q3
$9.81M Buy
+171,415
New +$9.83M 1.49% 29

Other funds holding HALO

South Street Advisors's HALO Position: Q2 2026 in Review

South Street Advisors increased its Halozyme (HALO) stake by 2.5% in Q2 2026, buying an estimated $392K and bringing the position to 238,689 shares worth $18.7M. The position accounts for 2.43% of the portfolio, ranked #20.

South Street Advisors first reported a position in HALO in Q3 2024 and has held it in 8 quarters since. 671 funds tracked by Wall St. Rank hold HALO as of Q2 2026.

  • South Street Advisors held 238,689 shares of Halozyme worth $18.7M as of Q2 2026.
  • South Street Advisors bought 5,749 Halozyme shares in Q2 2026, an estimated $392K.
  • Halozyme made up 2.43% of South Street Advisors's portfolio in Q2 2026, its #20 holding.
  • South Street Advisors first reported a position in Halozyme in Q3 2024 and has held it in 8 quarters since.
  • 671 funds tracked by Wall St. Rank held Halozyme as of Q2 2026.

Based on South Street Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.